Patent: 9,757,437
✉ Email this page to a colleague
Summary for Patent: 9,757,437
Title: | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
Abstract: | Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. |
Inventor(s): | Blair; Henry (Boston, MA), Beck; Thomas (Concord, MA), Ladner; Robert Charles (Ijamsville, MD) |
Assignee: | Dyax Corp. (Burlington, MA) |
Application Number: | 14/271,105 |
Patent Claims: | see list of patent claims |
Details for Patent 9,757,437
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | TRASYLOL | aprotinin | Injection | 020304 | 12/29/1993 | ⤷ Try a Trial | 2024-09-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |